August 2022 : Neoadjuvant durvalumab improves survival in early triple-negative breast cancer despite a modest pCR increase – follow-up data from GeparNuevo trial


We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.


GeparNuevo (NCT02685059) was a multicenter, prospective, randomized, double-blind, placebo-controlled phase II trial investigating the efficacy of neoadjuvant chemotherapy including nab-paclitaxel, followed by dose-dense epirubicin/cyclophosphamide (EC) with durvalumab versus placebo in patients with primary non-metastatic TNBC. Primary analysis showed that the addition of durvalumab to neoadjuvant chemotherapy led to a moderate increase in pCR rate by absolute 9% (p=0.287) (Loibl et al. Ann Oncol.2019).
This study reported the secondary endpoints included invasive disease-free survival (iDFS), distant disease-free survival (DDFS) and overall survival (OS), which were particularly interesting considering the moderate increase in pCR rate as well as the restriction of the checkpoint inhibitor to the neoadjuvant therapy phase.


  • This exploratory analysis shows a significant iDFS, DDFS and OS improvement with the addition of durvalumab to neoadjuvant chemotherapy
  • Survival improvement although no adjuvant checkpoint inhibitor therapy was given
  • Long-term effect is seen in pCR as well as non-pCR patients
  • The improved survival outcome with checkpoint inhibitor therapy is only partially explained by the increased pCR rate
  • Our results suggest that additional long-term anti-tumour effects are present

Conclusion: Durvalumab added to neoadjuvant chemotherapy in TNBC significantly improved survival despite a modest pCR increase and no adjuvant component of durvalumab. Additional studies are needed to clarify the optimal duration and sequence of CPIs in the treatment of early TNBC.

Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022 Aug 9:S0923-7534(22)03791-7. doi:10.1016/j.annonc.2022.07.


  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd